AstraZeneca's experimental antibody cocktail has been tested in a third stage to reduce serious illness or death in untreated patients, the British Pharmaceutical Company announced on Monday.
The drug, called AZD7442, reduced the risk of developing severe Covid-19 or dying by 50% in patients who were symptomatic for seven days or less, meeting the test target.
"Early intervention with our antibody can significantly reduce the progression of a serious illness and protection continues for more than six months," said Mene Pangalos, executive vice president of AstraZeneca.
The company will discuss the data with health authorities, he added without elaborating.
AstraZeneca is also developing the antibody cocktail as a treatment to protect people who do not have a strong enough immune response to the Covid-19 vaccine. Last week he sought emergency approval from US regulators for its use as a disease prevention drug.